Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication-Reference-Cited by-同舟云学术

Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication

Published:2022-01-27 Issue:2 Volume:38 Page:77-83
ISSN:1172-0360
Container-title:Drugs & Therapy Perspectives
language:en
Short-container-title:Drugs Ther Perspect

Author:

Balasundaram Mahesh Kumar,Singh Alok^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40267-022-00892-z.pdf

Reference23 articles.

1. Substance Abuse and Mental Health Services Administration. DSM-5 changes: implications for child serious emotional disturbance. Rockville: Substance Abuse and Mental Health Services Administration (US); 2016.

2. Caye A, Swanson JM, Coghill D, et al. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2019;24(3):390–408.

3. Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020;383(11):1050–6.

4. Budur K, Mathews M, Adetunji B, et al. Non-stimulant treatment for attention deficit hyperactivity disorder. Psychiatry (Edgmont). 2005;2(7):44–8.

5. Pozzi M, Carnovale C, Peeters GGAM, et al. Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: a meta-analysis. J Affect Disord. 2018;238:161–78.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An updated safety review of the current drugs for managing ADHD in children;Expert Opinion on Drug Safety;2023-10-24

2. Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder”;CNS Drugs;2022-11-04

3. Viloxazine ER (Qelbree ^® ): A New Non-Stimulant Option in the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder;Journal of Psychosocial Nursing and Mental Health Services;2022-07

4. Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials;Journal of Central Nervous System Disease;2022-01